Abstract: Compositions and methods for modulating neural outgrowth, including treating neural damage, via the major histocompatibility complex I (“MHC I”) molecule. Methods for identifying agents that reduce MHC I-induced inhibition of neurite outgrowth. Methods for promoting neural outgrowth comprising administering MHC I molecules (native, recombinant, or those encoded by gene fusion) or biologically-active fragments thereof. Pharmaceutical compositions comprising vectors comprising nucleic acid sequences encoding MHC I in operable linkage with a promoter and a pharmaceutically-acceptable carrier or diluent. Small interfering RNA (“siRNA”) that down-regulates expression of an MHC I gene.

Abstract: The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably, the methods and compositions utilize agents which interfere with the ability of the major histocompatibility complex (MHC) Class I molecule (MHC I) to inhibit neurite outgrowth. Such agents include antibodies directed to MHC I, MHC I fragments and/or analogs, and agents which interfere with MHC I interaction with its neuronal receptor and the receptor's signaling pathway.

Abstract: The invention relates to methods and compositions for treating neural damage caused by injury or disease, by enhancing neural outgrowth and/or repair responses in the nervous system. Preferably, the methods and compositions utilize agents which interfere with the ability of the major histocompatibility complex (MHC) Class I molecule (MHC I) to inhibit neurite outgrowth. Such agents include antibodies directed to MHC I, MHC I fragments and/or analogs, and agents which interfere with MHC I interaction with its neuronal receptor and the receptor's signaling pathway.